Advertisement

Topics

Shaky Q1 For Lupin But Upbeat On FDA Generics Reform, Biosimilars

09:18 EDT 3 Aug 2017 | SCRIP

Lupin reported a weak first quarter, but the management sees "tremendous upside" in opportunities arising from the US FDA’s recent...

      

Related Stories

 

Original Article: Shaky Q1 For Lupin But Upbeat On FDA Generics Reform, Biosimilars

NEXT ARTICLE

More From BioPortfolio on "Shaky Q1 For Lupin But Upbeat On FDA Generics Reform, Biosimilars"

Quick Search
Advertisement